Mesothelioma

Clinical trials of a new anticancer drug combination carried out by Cancer Research UK scientists at Newcastle University show that it has the potential to almost double the life expectancy of sufferers of mesothelioma – a form of lung cancer which affects around 1,700 people in the UK every year – according to a report published in the Journal of Clinical Oncology1.